TRHDE and neoplasm: Targeting the ncRNAs involved in this axis, such as AC008555.6, AC026356.1, TRHDE-AS1, or SNHG14, could potentially disrupt the regulatory mechanisms that lead to PLAUR overexpression, thereby reducing tumor progression and improving patient outcomes.